The biotechnology sector could be approaching another wave of merger and acquisition activity as major pharmaceutical companies confront a growing challenge: the expiration of patent protection on blockbuster medications. With an estimated $300 billion to $400 billion in pharmaceutical revenue facing patent-related pressure beginning in 2028, large drugmakers are increasingly focused on replenishing their development pipelines, potentially creating opportunities for smaller biotechnology companies.